Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

ATH/LAVI stock hub

ATH/LAVI has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ATH/LAVIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

287M

Athens Stock Exchange

Market data

Price

Recent price action with selectable time range.

ATH/LAVIATH/LAVI

—

Loading chart…

In the news

Latest news · ATH/LAVI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E58.2

P25 n/aP50 n/aP75 n/a

ROE9.2

P25 n/aP50 n/aP75 n/a

ROIC7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ATH/LAVI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

233

Groups with data

Currency

EUR

Showing 233 of 233 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Greece
Country code	GR
Employees	285
Employees Change	-14%
Employees Change Percent	-4.68
Enterprise value	EUR 313.7M
Exchange	Athens Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	GRS246073001
Last refreshed	2026-05-10
Market cap	EUR 287M
Price	EUR 1.7
Price currency	EUR
Rev Per Employee	219,592.98x
Sector	Healthcare
Sic	2834
Symbol	ath/LAVI
Website	https://lavipharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.09%
EV Earnings	52.41x
EV/EBIT	36.38x
EV/EBITDA	22.87x
EV/FCF	58.18x
EV/Sales	5.01x
FCF yield	1.88%
P/B ratio	5.09x
P/E ratio	58.15x
P/S ratio	4.59x
PE Ratio10 Y	32.67x
PE Ratio3 Y	80.52x
PE Ratio5 Y	56.72x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	13.78%
EBITDA Margin	20.64%
FCF margin	8.62%
Gross margin	48.42%
Gross Profit	EUR 30.3M
Gross Profit Growth	20.84%
Gross Profit Growth Q	106.8%
Gross Profit Growth3 Y	19.81%
Gross Profit Growth5 Y	13.31%
Net Income	EUR 6M
Net Income Growth	-33.36%
Net Income Growth Quarters	5%
Net Income Growth Years	0%
Net Income Growth3 Y	92.9%
Net Income Growth5 Y	23.38%
Pretax Margin	11.99%
Profit Margin	9.56%
Profit Per Employee	EUR 21,004
Profitable Years	10
ROA	4.22
Roa5y	3.58
ROCE	10
ROE	9.23
ROIC	6.96
Roic5y	6.69

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	17.53%
Cagr15y	2.67%
Cagr1y	119.37%
Cagr20y	-2.4%
Cagr3y	61.26%
Cagr5y	3.9%
Div CAGR10	0%
Div CAGR3	0%
Div CAGR5	0%
EPS Growth	-34.71
EPS Growth Quarters	3
EPS Growth Years	0
EPS Growth3 Y	-3.53
EPS Growth5 Y	-22.32
FCF Growth5 Y	31.45%
OCF Growth	48.13%
OCF Growth10 Y	27.74%
OCF Growth3 Y	25.81%
OCF Growth5 Y	18.51%
Revenue Growth	18.2x
Revenue Growth Q	55.41x
Revenue Growth Quarters	1x
Revenue Growth Years	3x
Revenue Growth3 Y	17.02x
Revenue Growth5 Y	10.71x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.49
Assets	EUR 130.2M
Cash	EUR 6.1M
Current Assets	EUR 53.2M
Current Liabilities	EUR 44M
Debt	EUR 32.8M
Debt EBITDA	EUR 2.39
Debt Equity	EUR 0.58
Debt FCF	EUR 6.08
Equity	EUR 56.4M
Interest Coverage	4.68
Liabilities	EUR 73.8M
Long Term Assets	EUR 77M
Long Term Liabilities	EUR 29.8M
Net Cash	EUR -26.7M
Net Cash By Market Cap	EUR -9.29
Net Debt EBITDA	EUR 2.07
Net Debt Equity	EUR 0.47
Net Debt FCF	EUR 4.95
Tangible Book Value	EUR 14.6M
Tangible Book Value Per Share	EUR 0.09
WACC	9.12

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.21
Inventory Turnover	1.49
Net Working Capital	EUR 15.1M
Quick ratio	0.65
Working Capital	EUR 9.2M
Working Capital Turnover	EUR 8.29

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.06%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	EUR 0.02
Dividend Years	1
Dividend Yield	1.18%
Last Dividend	EUR 0.02
Payout Ratio	56.48%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	402.76%
1Y total return	119.25%
200-day SMA	1.01
3Y total return	319.49%
50-day SMA	1.33
50-day SMA vs 200-day SMA	50over200
5Y total return	21.05%
All Time High	41.54
All Time High Change	-95.91%
All Time High Date	1999-09-16
All Time Low	0.16
All Time Low Change	948.15%
All Time Low Date	2016-09-19
ATR	0.07
Beta	1
Beta1y	1.47
Beta2y	1.21
Ch YTD	75.05
High	1.72
High52	1.72
High52 Date	2026-05-07
High52ch	-1.51%
Low	1.63
Low52	0.73
Low52 Date	2025-06-23
Low52ch	131.34%
Ma50ch	28.05%
Price vs 200-day SMA	68.29%
RSI	79.79
RSI Monthly	75.65
RSI Weekly	76.01
Sharpe ratio	2.11x
Sortino ratio	3.97
Total Return	1.23%
Tr YTD	75.05
Tr15y	48.44%
Tr1m	32.24%
Tr1w	11.71%
Tr3m	28.64%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 8.6M
Operating Income Growth	71.45
Operating Income Growth Q	794.6
Operating Income Growth3 Y	28.49
Operating Income Growth5 Y	10.8
Operating margin	13.78

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Net Borrowing	-1,765,000
Shares Institutions	2.2%
Shares Out	169,043,561
Shares Yo Y	-0.06%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 5.4M
Average Volume	302,330.1x
Bv Per Share	0.33
CAPEX	EUR -1.3M
Ch10y	356.5
Ch15y	34.76
Ch1m	32.24
Ch1w	11.71
Ch1y	113.9
Ch20y	-48.55
Ch3m	28.64
Ch3y	309.2
Ch5y	9.9
Ch6m	109.6
Change	1.07%
Change From Open	1.68
Close	1.68
Days Gap	-0.6
Depreciation Amortization	4,292,000
Dollar Volume	407,180.4
Earnings Date	2026-04-23
EBIT	EUR 8.6M
EBITDA	EUR 12.9M
EPS	EUR 0.03
F Score	8
FCF	EUR 5.4M
FCF EV Yield	1.72x
FCF Per Share	EUR 0.03
Financing CF	-5,350,000
Fiscal Year End	December
Founded	1,911
Graham Number	0.51107
Graham Upside	-69.9
Income Tax	EUR 2.5M
Investing CF	-938,000
Is Primary Listing	1
Last Earnings Date	2026-04-23
Last Report Date	2025-12-31
Last Split Date	2022-08-01
Last Split Type	Reverse
Lynch Fair Value	EUR 0.81
Lynch Upside	-52.12
Ma150	1.07
Ma150ch	58.54%
Ma20	1.48
Ma20ch	14.96%
Net CF	376,000
Next Earnings Date	2026-05-28
Open	1.67
P FCF Ratio	53.23
P OCF Ratio	43.08
Payment Date	2025-07-24
Position In Range	76.19
Ppne	21,967,000
Price Date	2026-05-08
Price EBITDA	EUR 22.22
Ptbv Ratio	19.68
Relative Volume	0.78x
Revenue	62,584,000x
Tax By Revenue	3.92x
Tax Rate	32.69%
Tr20y	-38.52%
Tr6m	109.63%
Volume	239,800
Z Score	1.7

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

ATH/LAVI dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.2%

$0.02 annual per share

Payout ratio

+56.5%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

0.0%

0 consecutive years of growth

Total shareholder yield

+1.2%

Dividend yield + buyback yield combined

Performance

ATH/LAVI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ATH/LAVI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+2.2%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.1%

Negative means the company is buying back shares.

Technical

ATH/LAVI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

79.8

Above 70: short-term overbought

Price vs 200-day MA

+68.3%

50/200-day relationship not available

Beta (5Y)

1.00

Moves roughly with the market

Sharpe ratio

2.11

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ATH/LAVI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ath/LAVI stock rating?

ath/LAVI is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ath/LAVI analysis?

The full report lives at /stocks/ath/LAVI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ath/LAVI?

The latest report frames ath/LAVI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ath/LAVI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.